Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VRC01-class precursor B cell receptors are a distinct subset of immunoglobulin receptors carried by naïve B cells capable of maturing into cells that produce VRC01-class broadly neutralizing antibodies against HIV-1. These receptors feature a heavy chain encoded by the IGHV1-2*02 allele paired with a light chain possessing an unusually short or glycine/serine-rich complementarity-determining region 3 (CDRL3). Their primary biological function is to recognize the CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein (Env). Engagement by germline-targeting immunogens such as eOD-GT8 leads to the activation and maturation of these naïve B cells, initiating the adaptive immune response necessary for the generation of potent and broadly acting HIV-1 neutralizing antibodies. VRC01-class precursor B cell receptors represent a key therapeutic target in the field of HIV vaccine development, with efforts focused on priming and activating these cells to enable long-term protective immunity.
Drugs/immunogens bind the VRC01-class precursor B cell receptor, activating naïve B cells that can mature into cells producing VRC01-class bnAbs
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VRC01-class precursor B cell receptor.